Indiana University School of Medicine

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

Retrieved on: 
Friday, November 3, 2023
Hepatocyte, Hynes Convention Center, American Association for the Study of Liver Diseases, Therapy, Hepatology, Liver, Pharmacokinetics, Sarcopenia, Safety, GALT, Glomerular filtration rate, GA 2, AM, Abstract (summary), Obesity, Indiana University School of Medicine, Cirrhosis, Data monitoring committee, Disease, Hepatic hydrothorax, Medical school, Indiana University, SC 4, K–Ca dating, Non-alcoholic fatty liver disease, AASLD, Dietary supplement, Pharmaceutical industry, Flour, Patient

NORCROSS, Ga., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will share five scientific presentations at The Liver Meeting™ 2023, hosted by the American Association for the Study of Liver Diseases (AASLD).

Key Points: 
  • NORCROSS, Ga., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will share five scientific presentations at The Liver Meeting™ 2023, hosted by the American Association for the Study of Liver Diseases (AASLD).
  • The Liver Meeting™ will be held November 10-14, 2023, in Boston, Mass.
  • “This year again we are happy to share some of the progress we have made in our global program with belapectin, our galectin-3 inhibitor.
  • We are also proud to bring additional knowledge to the field regarding liver cirrhosis, a disease that dramatically affects the lives of our patients and has been neglected for far too long,” said Pol Boudes, M.D., Chief Medical Officer of Galectin Therapeutics.

Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes

Retrieved on: 
Thursday, November 2, 2023
Survival, PBLA, Indiana University School of Medicine, Health, JDRF, Therapy, Hope, Mortality, MD, Pathology, Doctor of Philosophy, Disease, Research, Observation, Pediatrics, Riley Children's Foundation, News, Quality of life, Polyamine, School, Risk, Putrescine, University, U.S. News & World Report, ODC, Indiana University, Patient, MSN, Ornithine decarboxylase, DFMO, Pharmaceutical industry, Vaccine, Eflornithine, Medicine, T1D

A Phase 1 clinical study showed that DFMO treatment may provide metabolic benefits to preserve β cell function and health in T1D.

Key Points: 
  • A Phase 1 clinical study showed that DFMO treatment may provide metabolic benefits to preserve β cell function and health in T1D.
  • Data published in the journal Cell Reports Medicine investigated the mechanism of polyamines and polyamine inhibition by CPP-1X on β cell stress that plays a role in the onset of type 1 diabetes in in vitro and ex vivo models.
  • Results showed that DFMO treatment may preserve β cell function, reflected by C-peptide levels in patients with T1D through the modulation of urinary polyamines, in particular putrescine.
  • Results from these studies suggest that CPP-1X is a safe, oral treatment option that may improve β cell function and/or survival in recent onset T1D.

Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer Detection

Retrieved on: 
Sunday, October 22, 2023
Colorectal cancer, FDA, American College, Exact sciences, ACG, American Joint Committee on Cancer, Research, American College of Gastroenterology, NYU, Large intestine, Indiana University School of Medicine, Colonoscopy, Exact Sciences (company), FIT, New York University Grossman School of Medicine, Conditional sentence, Patient, Medical device, Pharmaceutical industry, MD, Medicine, Yeah! Yeah! Die! Die! Death Metal Symphony in Deep C

MADISON, Wis., Oct. 22, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced late-breaking data from the pivotal BLUE-C trial showing the next-generation Cologuard® test met all study endpoints, demonstrating 94 percent sensitivity for colorectal cancer (CRC) at 91% specificity, during the American College of Gastroenterology (ACG) Annual Meeting 2023.[1] Additionally, results show the next-generation Cologuard test was significantly more likely to detect cancer or precancer than fecal immunochemical testing (FIT)* (94% vs 67% and 43% vs 23%, respectively).[1]  Finally, the next-generation Cologuard test demonstrated higher sensitivity for the most clinically significant form of advanced precancerous lesions (high-grade dysplasia at 75%) than FIT (47%).[1]    

Key Points: 
  • In addition to superiority over FIT in sensitivity for both colorectal cancer and advanced precancerous lesions, the next-generation Cologuard test demonstrated 91% specificity.1 The specificity for FIT was 95%.
  • [1,3] For patients with a negative or non-neoplastic  findings on colonoscopy, specificity for the next-generation Cologuard test reached 93%.
  • "The findings indicate that the next-generation mt-sDNA test demonstrates even higher sensitivity for colorectal cancer screening (94%) and high-grade dysplasia (75%), compared with the current Cologuard test.
  • These findings suggest that, if FDA approved, the mt-sDNA test will be a valuable option in providing non-invasive colorectal cancer screening."

Vektor Medical Strengthens Its Medical Advisory Board with World-renowned Leaders in Electrophysiology

Retrieved on: 
Wednesday, October 11, 2023
Radiology, Health Technology, Health, Cardiology, Algorithm, ECG, Vector, Intelligence, Mass, Cardiac resynchronization therapy, Hospital, Indiana University School of Medicine, Artificial intelligence, Workflow, FDA, Harvard Medical School, Roman, Vektor, Patient, Arrhythmia, Massachusetts General Hospital, Pharmaceutical industry, Medical device, Medicine

Vektor Medical, a pioneer in arrhythmia care and developer of the only FDA-cleared non-invasive technology to accurately map arrhythmias using just 12-lead ECG data, is delighted to announce the expansion of its esteemed Medical Advisory Board.

Key Points: 
  • Vektor Medical, a pioneer in arrhythmia care and developer of the only FDA-cleared non-invasive technology to accurately map arrhythmias using just 12-lead ECG data, is delighted to announce the expansion of its esteemed Medical Advisory Board.
  • The newly expanded Medical Advisory Board, features preeminent electrophysiology leaders, including:
    "I'm very enthusiastic about vMap's potential to transform cardiac arrhythmia care.
  • I look forward to partnering with Vektor on its mission to revolutionize arrhythmia care and increasing access to safer, more personalized and affordable patient centered care across all communities and all human beings.”
    With this distinguished Medical Advisory Board, Vektor Medical is poised to further advance its impact in arrhythmia care.
  • Vektor Medical is committed to its mission to revolutionize cardiac arrhythmia care, and the addition of these prominent experts to its Medical Advisory Board represents a significant step towards realizing that vision.

Flesh-eating bacteria infections are on the rise in the US − a microbiologist explains how to protect yourself

Retrieved on: 
Monday, September 25, 2023
People, Infection, Tissue, Shellfish, Disease, Climate, Diabetes, Amputation, HIV, Necrotizing fasciitis, Liver disease, Indiana University School of Medicine, Sore, Fever, Cancer, Immunity, Seafood, Wound, CDC, Blood, Swimming, Eating, Streptococcus, Swelling, Time, Vibrio vulnificus, Water, Korea Disease Control and Prevention Agency, Cyclone, Blister, Center, Bacteria, Ulcer, Climate change, Skin discoloration, Red, Skin, Microbiology, Vaccine, Oyster farming, Vibrio

Flesh-eating bacteria sounds like the premise of a bad horror movie, but it’s a growing – and potentially fatal – threat to people.

Key Points: 
  • Flesh-eating bacteria sounds like the premise of a bad horror movie, but it’s a growing – and potentially fatal – threat to people.
  • In September 2023, the Centers for Disease Control and Prevention issued a health advisory alerting doctors and public health officials of an increase in flesh-eating bacteria cases that can cause serious wound infections.

What does ‘flesh-eating’ mean?

    • There are several types of bacteria that can infect open wounds and cause a rare condition called necrotizing fasciitis.
    • These bacteria do not merely damage the surface of the skin – they release toxins that destroy the underlying tissue, including muscles, nerves and blood vessels.
    • The bacterial species group A Streptococcus, or group A strep, is the most common culprit behind necrotizing fasciitis.

How do you catch flesh-eating bacteria?

    • Most infections in the U.S. occur in the warmer months, between May and October.
    • People who swim, fish or wade in these bodies of water can contract the bacteria through an open wound or sore.
    • Vibrio vulnificus can also get into seafood harvested from these waters, especially shellfish like oysters.

Why are flesh-eating bacteria infections rising?

    • But rising ocean temperatures due to global warming are creating new habitats for this type of bacteria, which can now be found along the East Coast as far north as New York and Connecticut.
    • A recent study noted that Vibrio vulnificus wound infections increased eightfold between 1988 and 2018 in the eastern U.S.
    • Climate change is also fueling stronger hurricanes and storm surges, which have been associated with spikes in flesh-eating bacteria infection cases.

What are symptoms of necrotizing fasciitis? How is it treated?

    • Early symptoms of an infected wound include fever, redness, intense pain or swelling at the site of injury.
    • If you have these symptoms, seek medical attention without delay.
    • Necrotizing fasciitis can progress quickly, producing ulcers, blisters, skin discoloration and pus.

How do I protect myself?

    • People who have a fresh cut, including a new piercing or tattoo, are advised to stay out of water that could be home to Vibrio vulnificus.
    • Wounds that occur while fishing, preparing seafood or swimming should be washed immediately and thoroughly with soap and water.
    • This includes people taking immunosuppressive medications or those who have pre-existing conditions such as liver disease, cancer, HIV or diabetes.

EmVenio Research continues momentum of team growth with two new principal investigators

Retrieved on: 
Thursday, September 21, 2023
Molecular biology, Doctor of Medicine, University, Diabetes, Internal medicine, Smoking and Health: Report of the Advisory Committee to the Surgeon General of the United States, Physician, American Board of Internal Medicine, Georgetown University School of Medicine, Cardiovascular disease, Infection, University School, Physiology, DRS, Research, Georgetown University, American Board of Commissioners for Foreign Missions, Health care access among Dalits in India, Indiana University School of Medicine, Surgeon, Accreditation, Knowledge, Growth, Jan Vansina, National Board of Medical Examiners, Pharmaceutical industry, Medical device, Nursing, Science, Indiana University

DURHAM, N.C., Sept. 21, 2023 /PRNewswire/ -- Clinical research organization EmVenio Research recently announced the addition of Michelle Mallitz, M.D. and Thomas Wade, M.D. to its team to serve as principal investigators. In their roles, they will oversee and conduct objective clinical research to ensure independent, high quality and reproducible results, as well as manage oversight of compliance, financial, personnel and other related aspects of research projects. Coming from varying medical backgrounds, Drs. Mallitz and Wade bring a depth of knowledge and experience to the EmVenio team, allowing the research organization to conduct trials addressing a wider range of infectious diseases and therapeutic areas.

Key Points: 
  • DURHAM, N.C., Sept. 21, 2023 /PRNewswire/ -- Clinical research organization EmVenio Research recently announced the addition of Michelle Mallitz, M.D.
  • "The addition of these two incredible principal investigators is proof that EmVenio's growth is focused on quality and not quantity," said Thad Wolfram, EmVenio president.
  • "These individuals bring a level of expertise and skill that opens more doors for our team to conduct a multitude of research studies for pharmaceutical sponsors and clinical research organizations.
  • Dr. Thomas Wade holds nearly 23 years of medical practice and clinical research experience, serving as a principal investigator and practicing internal medicine.

Vera Bradley Foundation for Breast Cancer Raises $1,513,713 for Breast Cancer Research

Retrieved on: 
Monday, September 18, 2023
Volunteering, Partnership, Roswell Park Comprehensive Cancer Center, Indiana University School of Medicine, Hope, Research, University of Virginia Cancer Center, Breast Cancer Awareness Month, National Cancer Institute, Breast cancer, School, Classic, NCI, National Breast Cancer Foundation (Australia), Disease, Dietary supplement, Medicine

FORT WAYNE, Ind., Sept. 17, 2023 (GLOBE NEWSWIRE) -- The Vera Bradley Foundation for Breast Cancer (the "Foundation") today announced a donation of $1,513,713 to support the Vera Bradley Foundation Center for Breast Cancer Research at the Indiana University School of Medicine (“IU School of Medicine”).

Key Points: 
  • FORT WAYNE, Ind., Sept. 17, 2023 (GLOBE NEWSWIRE) -- The Vera Bradley Foundation for Breast Cancer (the "Foundation") today announced a donation of $1,513,713 to support the Vera Bradley Foundation Center for Breast Cancer Research at the Indiana University School of Medicine (“IU School of Medicine”).
  • The Foundation’s donation announcement was shared at the 29th annual Vera Bradley Foundation for Breast Cancer Classic (the “Classic”), which gathered guests, players, and volunteers from across the country to raise funds for breast cancer research.
  • More than 35 members of the Vera Bradley Foundation Center for Breast Cancer Research team at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center (the “IU Cancer Center”) work collaboratively with laboratory, clinical, translational and population/prevention researchers in a multi-disciplinary approach.
  • “For the past 30 years, the Vera Bradley Foundation for Breast Cancer has been steadfastly committed to raising funds for breast cancer research,” noted Stephanie Scheele, Executive Director of the Vera Bradley Foundation for Breast Cancer.

Butterfly Network Reports Success in Majority of U.S. Medical Schools; Includes Nation’s Largest Medical School, Indiana University School of Medicine

Retrieved on: 
Thursday, September 14, 2023
Surgery, Baby, Maternity, Other Health, Public Policy, Government, Radiology, Software, Oncology, Hardware, Medical Devices, Data Management, Healthcare Reform, Hospitals, Technology, Clinical Trials, Cardiology, Women, Practice Management, Seniors, Veterinary, Physical Therapy, Nursing, Managed Care, Pets, Medical Supplies, FDA, Health, Consumer, Network, Emergency medicine, Internal medicine, Butterfly network, Madison Center for Educational Affairs, Curriculum, University School, OB-GYN, IUSM, Movement, POCUS, Anesthesia, School, Student, Indiana University School of Medicine, MD, Physician, Faculty, Nursing care plan, Ecosystem, News, Butterfly

The update follows news from Indiana University School of Medicine (IUSM) earlier this week announcing its investment in Butterfly iQ+ technology and enhanced training for its medical students, as well as faculty, residents and fellows across family medicine, internal medicine, emergency medicine, anesthesia, OB-GYN, surgery and critical care.

Key Points: 
  • The update follows news from Indiana University School of Medicine (IUSM) earlier this week announcing its investment in Butterfly iQ+ technology and enhanced training for its medical students, as well as faculty, residents and fellows across family medicine, internal medicine, emergency medicine, anesthesia, OB-GYN, surgery and critical care.
  • Butterfly’s POCUS technology can be found onsite at the majority of U.S. medical schools today, with an increasing number of programs adopting a hands-on, one-probe-per-student training model.
  • Butterfly’s device sales into U.S. medical schools more than doubled in volume in the first half of 2023 over 2022, as schools continue to realize the value of POCUS.
  • IUSM now leads the charge of academic institutions driving a fundamental shift in medical education.

n-Lorem Foundation Founder and CEO, Stanley Crooke, M.D., Ph.D., Awarded the Steven C. Beering Award

Retrieved on: 
Friday, September 8, 2023
Biotechnology, Pharmaceutical, Genetics, Health, Lecture, Indiana University School of Medicine, Drug discovery, Asos, ASO, Research, Gene, Patient, DSM-IV codes, Pharmaceutical industry, Medical device

n-Lorem, a nonprofit foundation , today announced that n-Lorem founder and CEO, Stanley Crooke, M.D., Ph.D., has been awarded the 2022 Steven C. Beering Award.

Key Points: 
  • n-Lorem, a nonprofit foundation , today announced that n-Lorem founder and CEO, Stanley Crooke, M.D., Ph.D., has been awarded the 2022 Steven C. Beering Award.
  • The Steven C. Beering Award is given by Indiana University School of Medicine to one person each year.
  • Past winners of this prestigious award include Dr. George Church, Dr. William Kaelin, and Dr. George Stark.
  • The Steven C. Beering Award for the advancement of biomedical science will be presented to Dr. Crooke today at the Indiana University School of Medicine during a lecture and award presentation .

Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes

Retrieved on: 
Thursday, August 24, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Linda, Partnership, University, Pediatrics, Therapy, NOD, Outcomes research, Pediatric endocrinology, Immune tolerance, Pancreas, University of California, Research, Multiple sclerosis, Inflammation, Autoimmunity, Assistant, TCR, Harvard Medical School, ITN, Behavior, Indiana University School of Medicine, Patient, Division, Lymph, Insulitis, Benaroya Research Institute, Endocrinology, Biology, Joslin Diabetes Center, Pharmaceutical industry, Nursing, T1D, Regulatory T cell, Medicine

“We are rapidly developing ABA-201 for T1D and expect to begin clinical studies in 2025.

Key Points: 
  • “We are rapidly developing ABA-201 for T1D and expect to begin clinical studies in 2025.
  • Additional non-clinical studies have established the role of Tregs in suppressing β-cell injury, a further potential benefit of the approach.
  • “This second program expands the scope of our pioneering Treg cell-based approach to patients with T1D.
  • This group brings deep expertise in T1D pathogenesis and the clinical development of novel therapeutics.